CA-VOXELDANCE
25.5.2021 07:14:09 CEST | Business Wire | Press release
Voxeldance , a leading provider of digital manufacturing software for additive 3D printing, today announced the appointment of Robert Yusin as Chief Operating Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005861/en/
Yusin will lead operations and collaborate with the executive team to drive global growth. He brings more than 25 years of global experience in manufacturing applications, security, network, storage, and cloud in software and hardware. He was formerly one of three founders at Oqton. He also served as Director of Sales/business development at Autodesk where he pioneered the Asia market for the Autodesk Consumer Group (ACG) division. His previous experience includes executive roles at Accelops (Fortinet), Trustwave, Symantec, Loglogic (TIBCO), McAfee, and StorageTek. Yusin has built and managed companies and functions from zero to $300+ million in revenue.
“Robert brings a tremendous record of success and I am excited to add him to the company’s executive team,” said Zhang Chaoxin, CEO of Voxeldance. “His experience with startups with successful exits and domain expertise in manufacturing will help Voxeldance expand operations to support the next phase of growth.”
“Voxeldance offers software solutions that will integrate with the end-to-end digital factory for customers and partners,” said Robert Yusin. “The leadership team has built a great company as evidenced by the portfolio of large enterprise customers and partners; I look forward to contributing to the team.”
Additional Resources:
Official website: https://www.voxeldance.com
Video site: https://www.youtube.com/channel/UC1d6KPoLhTjwREMPRuG2MFg?view_as=subscriber
Twitter: https://twitter.com/VoxelDance
Facebook: https://www.facebook.com/VoxelDance-666723630455229/
WeChat Public Number: VoxelDance
LinkedIn: http://www.linkedin.com/company/Voxeldance
Customer case studies and evaluations: https://voxeldance.com/blog
Sales inquiry: info@voxeldance.com
About Voxeldance:
Voxeldance is the recognized leader for manufacturing software solutions for additive 3D printing, with a high adoption rate in use with hardware technology partners and service bureaus that integrate Voxeldance flagship additive software with their solutions. Voxeldance products are secure, cost effective and are easily adaptable to integrate with existing technology for the digital factory. The software products are built on technology advancements that will proactively accelerate workflow processes allowing the operator to effectively streamline hours of time for operational improvements in supporting many vertical use cases. Voxeldance is headquartered in Shanghai China and can be found online at http://www.voxeldance.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005861/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom